# NCT01564537 (NCT01564537)

> A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01564537
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
- Interventions: Ixazomib; Lenalidomide; Dexamethasone; Placebo
- Enrollment: 722
- Primary outcome: Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 7
- YouTube: 3
- Podcasts: 1
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct01564537

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01564537", "email": "<work email>"}; the inbox owner confirms by the emailed link.